廣告
香港股市 將收市,收市時間:3 小時 45 分鐘
  • 恒指

    16,550.90
    -186.20 (-1.11%)
     
  • 國指

    5,787.25
    -60.90 (-1.04%)
     
  • 上證綜指

    3,073.03
    -11.90 (-0.39%)
     
  • 滬深300

    3,592.42
    -11.11 (-0.31%)
     
  • 美元

    7.8203
    +0.0015 (+0.02%)
     
  • 人民幣

    0.9199
    -0.0002 (-0.02%)
     
  • 道指

    38,790.43
    +75.66 (+0.20%)
     
  • 標普 500

    5,149.42
    +32.33 (+0.63%)
     
  • 納指

    16,103.45
    +130.25 (+0.82%)
     
  • 日圓

    0.0519
    -0.0002 (-0.48%)
     
  • 歐元

    8.5019
    +0.0007 (+0.01%)
     
  • 英鎊

    9.9490
    -0.0010 (-0.01%)
     
  • 紐約期油

    82.72
    0.00 (0.00%)
     
  • 金價

    2,165.10
    +0.80 (+0.04%)
     
  • Bitcoin

    65,114.14
    -2,683.11 (-3.96%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal

  • Ginkgo Bioworks Holdings Inc (NYSE: DNAagreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction.

  • Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo.

  • Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, including machine learning and data science tools for exploring genetic design space.

  • The agreement represents Ginkgo's largest acquisition to date and is expected to significantly enhance Ginkgo's platform by integrating robust automation and software capabilities.

  • Ginkgo customers will also benefit from expanding Ginkgo's library of biological assets ("Codebase") following the transaction.

  • The transaction is expected to be completed by the first quarter of 2023.

  • Price Action: DNA shares are down 4.62% at $2.79, and ZY stock is up 18.8% at $2.38 during the market session on the last check Monday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.